<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00821899</url>
  </required_header>
  <id_info>
    <org_study_id>BMATxDM1</org_study_id>
    <nct_id>NCT00821899</nct_id>
  </id_info>
  <brief_title>Bone Marrow Autotransplantation in Type 1 Diabetes</brief_title>
  <official_title>Regeneration of Insulin Production in Patients With Type 1 Diabetes by Autologous Bone Marrow Blood Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project evaluates the effectiveness of the administration of autologous bone marrow
      blood in patients with brittle type 1 diabetes mellitus to restore insulin secretion. After
      mobilization of hematopoietic progenitors (G-CSF) during 3 days, 50 to 90 mL of bone marrow
      blood will be obtained by multifunction in the posterior iliac crest. The material obtained
      will be implanted into the pancreas through the magna pancreatic artery after femoral
      catheterization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate glycosylated hemoglobin 1,3,6, and 12 months after autologous bone marrow blood administration.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate number of hypoglycemias 1,3,6, and 12 months after autologous bone marrow blood administration.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate insulin dose 1,3,6, and 12 months after autologous bone marrow blood administration.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate GADab titers and treatment tolerance 1,3,6, and 12 months after autologous bone marrow blood administration.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">3</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>administration of autologous bone marrow blood</intervention_name>
    <description>administration of autologous bone marrow blood through magna pancreatic artery after femoral catheterization once during 12-month study period</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetes type 1 patients

          -  18 to 50 years of age

          -  more than 5 years of evolution of the disease

          -  brittle diabetes (HbA1c &gt; 8.5 % with intensified treatment or severe hypoglycemia
             episodes

        Exclusion Criteria:

          -  history of cancer

          -  hematologic alterations

          -  infectious disease positivity (HIV, HCV etc.)

          -  diabetic nephropathy

          -  cardiac failure

          -  liver disease

          -  autoimmune systemic disease

          -  allergy to iodine contrast or anesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esmatjes Enric, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Enric Esmatjes</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <last_update_submitted>March 19, 2012</last_update_submitted>
  <last_update_submitted_qc>March 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Enric Esmatjes</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>diabetes type 1</keyword>
  <keyword>bone marrow transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

